Christopher Demetriades, | |
3501 Mills Ave Fl 6, Austin, TX 78731-6309 | |
(512) 324-2000 | |
Not Available |
Full Name | Christopher Demetriades |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 3501 Mills Ave Fl 6, Austin, Texas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154990398 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Christopher Demetriades, 3501 Mills Ave, Austin, TX 78731-6309 Ph: () - | Christopher Demetriades, 3501 Mills Ave Fl 6, Austin, TX 78731-6309 Ph: (512) 324-2000 |
News Archive
The Cancer Prevention and Research Institute of Texas has awarded new grants totaling $1.8 million to two University of Texas at Dallas scientists for their research related to lung and kidney cancers.
Recently, the accuracy of current methods of pain assessment in babies have been called into question. New research from London-area hospitals and the University of Oxford measures brain activity in infants to better understand their pain response.
Two new studies raise public health concerns about increasing antiviral resistance among certain influenza viruses, their ability to spread, and a lack of alternative antiviral treatment options.
Repros Therapeutics Inc. today announced it has commenced randomization of subjects into its Phase II Androxal® study in the treatment of type 2 diabetes (T2DM) in men with low testosterone. Low testosterone and T2DM are co-morbid conditions in a significant number of men. The study is being conducted at nine sites across the US including both academic and private practices and will enroll up to 150 patients.
› Verified 9 days ago